# PhI to Solid Tumors and PhII to Locally Advanced or mTNBC

> **NCT05390710** · PHASE1 · COMPLETED · sponsor: **Laekna Limited** · enrollment: 21 (actual)

## Conditions studied

- Solid Tumor
- TNBC - Triple-Negative Breast Cancer

## Interventions

- **COMBINATION_PRODUCT:** LAE005 + Afuresertib + Nab-Paclitaxel

## Key facts

- **NCT ID:** NCT05390710
- **Lead sponsor:** Laekna Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-12
- **Primary completion:** 2023-12-11
- **Final completion:** 2023-12-11
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05390710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05390710, "PhI to Solid Tumors and PhII to Locally Advanced or mTNBC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05390710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*